The changing paradigm of managing Merkel cell carcinoma in Australia: An expert commentary-Reference-Cited by-同舟云学术

The changing paradigm of managing Merkel cell carcinoma in Australia: An expert commentary

Published:2020-08-05 Issue:6 Volume:16 Page:312-319
ISSN:1743-7555
Container-title:Asia-Pacific Journal of Clinical Oncology
language:en
Short-container-title:Asia‐Pac J Clin Oncol

Author:

Kok David L.¹²^ORCID,Wang Annie¹,Xu Wen³,Chua Margaret S. T.¹,Guminski Alexander⁴,Veness Michael⁵,Howle Julie⁶,Tothill Richard²,Kichendasse Ganessan⁷,Poulsen Michael⁸,Sandhu Shahneen¹²,Fogarty Gerald⁹

Affiliation:

1. Peter McCallum Cancer Centre Melbourne Victoria Australia

2. University of Melbourne Melbourne Victoria Australia

3. Princess Alexandra Hospital Brisbane Queensland Australia

4. Royal North Shore Hospital St. Leonards New South Wales Australia

5. Westmead Hospital University of Sydney Westmead New South Wales Australia

6. Westmead Hospital Westmead New South Wales Australia

7. Flinders Medical Centre Bedford Park South Australia Australia

8. ROPART South Brisbane South Brisbane Queensland Australia

9. St Vincent's Hospital Sydney New South Wales Australia

Publisher

Wiley

Subject

Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ajco.13407

Reference72 articles.

1. Australian Institute for Health and Welfare.AIHW Australian Cancer Database.2010.

2. Merkel cell carcinoma: Current US incidence and projected increases based on changing demographics

3. The Etiology and Epidemiology of Merkel Cell Carcinoma

4. Prognostic factors in Merkel cell carcinoma: Analysis of 240 cases

5. Clonal Integration of a Polyomavirus in Human Merkel Cell Carcinoma

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current status of Merkel cell carcinoma: Epidemiology, pathogenesis and prognostic factors;Virology;2024-11

2. Localized Merkel cell carcinoma treatment considerations: a response to the forty-year experience at the Peter MacCallum cancer centre;BMC Cancer;2024-06-03

3. Combination of peptide receptor radionuclide therapy and immune checkpoint inhibitor in metastatic Merkel cell carcinoma;IRAN J NUCL MED;2024

4. S2k Guideline – Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) – Update 2022;JDDG: Journal der Deutschen Dermatologischen Gesellschaft;2023-03

5. S2k‐Leitlinie – Merkelzellkarzinom – Update 2022;JDDG: Journal der Deutschen Dermatologischen Gesellschaft;2023-03